Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UV1 Vaccine with Nivolumab and Ipilimumab in Malignant Pleural Mesothelioma
NCT04300244Phase 2Active, not recruiting
- Sponsor
- Åslaug Helland
- Start
- May 2020
- Primary completion
- Mar 2025
- Modality
- Split/Subunit Vaccines, Peptide-based Cancer Vaccines
- Countries
- 5
01
Overview
A Phase 2 trial of UV1 in malignant pleural mesothelioma (MPM), sponsored by Åslaug Helland. Started May 2020; status: active, not recruiting.
02
Drugs
UV1
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT04300244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04300244.